2-(甲氧基甲基)-4(1H)-嘧啶酮 | 34274-23-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-(甲氧基甲基)-4(1H)-嘧啶酮
• 英文名称: (R)-2-Methoxymethyl4-hydroxy-pyrimidine
• 英文别名: 4-Hydroxy-2-methyloxymethylpyrimidine；2-methoxymethyl-3H-pyrimidin-4-one；2-(Methoxymethyl)pyrimidin-4(1H)-one；2-(methoxymethyl)-1H-pyrimidin-6-one
• CAS: 34274-23-2
• 化学式: C₆H₈N₂O₂
• 分子量: 140.142
• InChiKey: BWTHMJYOWBVUDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2-(甲氧基甲基)-4(1H)-嘧啶酮 在 三氯氧磷 作用下， 生成 4-氯-2-甲氧基甲基嘧啶
  参考文献：
  名称：

  Substituted thienoimidazole derivatives, a process for the preparation

  摘要：

  取代噻唑咪唑衍生物，其制备方法，含有它们的药物组合物，以及将其用作胃酸分泌抑制剂、胃粘膜保护剂和治疗肠道炎症的药物的用途。该发明涉及以下式的化合物：其中A代表T表示-S-、-SO-或-SO2-，R1至R10、X、Y和Z的含义如描述中所示，以及其制备方法、含有它们的药物组合物，以及将其用作胃酸分泌抑制剂、胃粘膜保护剂和治疗肠道炎症的用途。

  公开号：

  US04956366A1
• 作为产物：
  描述：

  (1E)-2-甲氧基乙脒 、 sodium 2-ethylmalonaldehyde 生成 2-(甲氧基甲基)-4(1H)-嘧啶酮
  参考文献：
  名称：

  IFE, ROBERT J.;BROWN, THOMAS H.

  摘要：

  DOI：

文献信息

• Compounds for treating and preventing diabetic complications
  申请人：Pfizer Inc.

  公开号：US06294538B1

  公开（公告）日：2001-09-25

  This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R is as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

  这项发明涉及式I的山梨醇脱氢酶抑制化合物，其中R如规范中所定义。这项发明还涉及含有这些化合物的药物组合物，以及通过向患有糖尿病且因此有发生这些并发症风险的哺乳动物施用这些化合物来治疗或预防糖尿病并发症，特别是糖尿病神经病变、糖尿病肾病和糖尿病心肌病。这项发明还涉及含有本发明式I化合物与醛糖还原酶抑制剂的组合物的药物组合物，以及用于治疗或预防糖尿病并发症的方法。这项发明还涉及含有本发明式I化合物与NHE-1抑制剂的组合物的药物组合物，以及用于治疗心肌病和其他心脏相关问题的方法。这项发明还涉及用于合成式I化合物的某些中间体以及制备这些中间体的方法。
• Pyrimidylalkylthio benzimidale compounds, pharmaceutical compositions
  申请人：Smith Kline & French Laboratories Limited

  公开号：US04777172A1

  公开（公告）日：1988-10-11

  This invention relates to 2- and 4-pyrimidinylmethylsulphinyl(and thio)benzimidazoles in which the pyrimidyl group is substituted by an optionally substituted amino group. These compounds inhibit exogenously and endogenously stimulated gastric acid secretion.

  本发明涉及2-和4-嘧啶甲基磺酰基（和硫）苯并咪唑，其中嘧啶基被一个可选择取代的氨基基团取代。这些化合物可以抑制外源性和内源性刺激的胃酸分泌。
• Substituted pyrimidine derivatives, a process for the preparation
  申请人：Hoechst Aktiengesellschaft

  公开号：US05215990A1

  公开（公告）日：1993-06-01

  Pyrimidine derivatives of the formula I ##STR1## in which R.sup.1, R.sup.2, X and Y have the stated meaning, the salts thereof and a process for the preparation thereof are described. Because of their sorbitol-accumulating activity, they are suitable for use as reagents for an advantageous pharmacological screening model for testing aldose reductase inhibitors.

  本文介绍了公式I中的嘧啶衍生物##STR1##，其中R.sup.1，R.sup.2，X和Y具有所述的含义，以及其盐和制备过程。由于它们具有山梨醇积累活性，因此它们适用于作为有利的药理筛选模型的试剂，用于测试醛固酮还原酶抑制剂。
• Sorbitol dehydrogenase inhibitors
  申请人：——

  公开号：US20040077671A1

  公开（公告）日：2004-04-22

  This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, 1 wherein R 1 , R 2 and R 3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

  本发明涉及公式I的山梨醇脱氢酶抑制剂，其中R1、R2和R3如规范中所定义。本发明还涉及含有这些化合物的制药组合物以及通过向患有糖尿病且因此有发展这些并发症风险的哺乳动物投与这些化合物来治疗或预防糖尿病并发症，特别是糖尿病神经病、糖尿病肾病、糖尿病微血管病、糖尿病大血管病和糖尿病心肌病的方法。本发明还涉及一种公式I化合物与醛糖还原酶抑制剂的组合物制药组合物以及用于治疗或预防糖尿病并发症的方法。本发明还涉及一种公式I化合物与NHE-1抑制剂的组合物制药组合物以及用于治疗心肌病和其他心脏相关问题的方法。本发明还涉及用于合成公式I化合物的某些中间体以及制备这些中间体的方法。
• Pyrimidylalkylthio benzimidazole compounds, pharmaceutical compositions
  申请人：Smith Kline & French Laboratories

  公开号：US04820708A1

  公开（公告）日：1989-04-11

  This invention relates to 2- and 4-pyrimidinylmethylsulphinyl(and thio)benzimidazoles in which the pyrimidyl group is substituted by an optionally substituted amino group. These compounds inhibit exogenously and endogenously stimulated gastric acid secretion.

  该发明涉及2-和4-嘧啶基甲基亚砜基（和硫）苯并咪唑，其中嘧啶基团被一个可选择性取代的氨基团取代。这些化合物能够抑制外源性和内源性刺激的胃酸分泌。